WVU cancer researcher and Assistant Professor of Pharmaceutical Sciences Wei Du, MD, PhD, teamed up with researchers from Cincinnati Children’s Hospital Medical Center to focus on improving outcomes and reducing side effects of traditional stem cell transplant. Their work was recently published in Leukemia, one of the top journals in hematology.
The studies identify an innovative drug that targets Cdc42, a member of one of the Rho GTPase family, which increases bone marrow accessibility and therefore improves stem cell transplant outcome. This project is an extension of previous research in the field of Rho GTPase family in hematopoiesis and is intended to address the urgent and important need for stem cell transplantation. Dr. Du’s work offers a novel preparative regimen for stem cell transplantation in treating bone marrow failure and other blood diseases. They are currently working on establishing improved methods for blood stem cell harvest and transplantation that could significantly impact future stem cell therapies for patients with leukemia and other blood cancers.
In the News:
Two Studies Describe Improved Approach to Bone Marrow Transplant - Cincinnati Children's Newsroom
MORGANTOWN, W.Va. – Lori Hazlehurst, Ph.D., Professor (WVU School of Pharmacy - Pharmaceutical Sciences and Co-Leader of the WVU Cancer Institute Research Program the Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, has been named as the Associate Director for Basic Research at the WVU Cancer Institute. In this role, she will work closely with Dr. Richard Goldberg, Institute Director, and the leadership team of the WVU Cancer Institute to implement strategic goals to increase the impact of basic and translational cancer research at WVU. The primary strategy is to increase the number of NIH funded investigators focused on cancer research at WVU